For the Inventor, By the Inventor

Enter assignee name

Andover, MA, United States of America

Deuterx, LLC

USPTO Granted Patents = 23

% Expired Patents = 8.7

CIPO Patents = 1

EPO Patents = 3

Forward Citations = 358

Loading Chart...

Loading Chart...

5 inventors (with patents filed for the assignee):

Sheila DeWitt (14 out of 21 patents)

Anthony W Czarnik (6 out of 32 patents)

Vincent Jacques (5 out of 30 patents)

4. Leonardus H T Van Der Ploeg (2 out of 32 patents)

5. William Perrault (1 out of 1 patent)

6. Leonardus Van Der Ploeg (4 patents)

7. Sheila Dewitt (0 patent)

23 patents: Sort by Forward Citations

1. 12180137 - Solid forms of enantiopure deuterium-enriched bupropion and methods of use thereof (2024-12-31),

2. 11535603 - Deuterium-enriched piperidinonyl-oxoisoindolinyl acetamides and methods of treating medical disorders using same (2022-12-27),

3. 11491156 - 3-(substituted-4-oxoquinazolin-3(4)-yl)-3-deutero-piperidine-2,6-dione derivatives and compositions comprising and methods of using the same (2022-11-08),

4. 11040925 - 3-(5-substituted-4-oxoquinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives and compositions comprising and methods of using the same (2021-06-22),

5. 10555946 - 3-(substituted-4-oxoquinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives and compositions comprising and methods of using the same (2020-02-11),

6. 10202316 - 3-(5-substituted-4-oxoquinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives and compositions comprising and methods of using the same (2019-02-12),

7. 10189858 - Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same (2019-01-29),

8. 10188639 - Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone (2019-01-29),

9. 9925175 - Deuterium-enriched pioglitazone (2018-03-27),

10. 9913845 - 3-(substituted-4-oxoquinazolin-3(4H)-yl)-3-deutero-piperidine-2,6-dione derivatives and compositions comprising and methods of using the same (2018-03-13),

11. 9833445 - 5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same (2017-12-05),

12. 9809603 - Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same (2017-11-07),

13. 9732031 - Methods of treating neurological and other disorders using enantiopure deuterium-enriched bupropion (2017-08-15),

14. 9540340 - [object Object] (2017-01-10),

15. 9416117 - 5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same (2016-08-16),

DeuteRx is a leading biotechnology company specializing in the development of novel therapeutics. With a focus on delivering innovative solutions to unmet medical needs, DeuteRx is committed to improving patient outcomes. Through rigorous research and development, the company aims to discover and develop transformative drugs that address various diseases and conditions. For more information, please visit our website.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Sep 15 2026

23 Patents

#13 in Andover, MA

#862 in Massachusetts

#14,383 in US

#27,581 in the World

Andover, MA, United States of America

Deuterx, LLC

Forward Citations = 358

5 inventors:

Sheila DeWitt (14 out of 21 patents)

Anthony W Czarnik (6 out of 32 patents)

Vincent Jacques (5 out of 30 patents)

4. Leonardus H T Van Der Ploeg (2 out of 32 patents)

5. William Perrault (1 out of 1 patent)

Please report any incorrect information to [email protected]

Loading…